Where guidance meets the local antibiogram: a three-year, single-center laboratory-based study of ertapenem-only nonsusceptibility, cefotaxime–ceftazidime discordance, and urinary susceptibility in Enterobacterales

Background Local antibiograms are essential for monitoring resistance and adapting treatment guidance to available antibiotics in resource-constrained settings. We examined resistance trends, discordant β-lactam susceptibility, and urinary susceptibility profiles in Enterobacterales to identify stewardship priorities. Methods This three-year, single-center, laboratory-based retrospective cross-sectional study included Enterobacterales from reporting years 2023–2025. We retained the first isolate per patient, species, and year. Resistance definitions incorporated the imipenem exception for Morganella , Proteus , and Providencia . Ertapenem-only nonsusceptibility required ertapenem nonsusceptibility and susceptibility to both meropenem and imipenem. Annual trends were assessed using the Cochran–Armitage test. Results Of 2,190 Enterobacterales isolates, 1,638 from 1,320 patients were retained. The proportion of isolates with carbapenem resistance declined from 8.4% in 2023 to 2.7% in 2025, and carbapenem nonsusceptibility from 12.6% to 5.4% (both p < 0.001). Cefotaxime resistance remained between 27.7% and 30.3% ( p = 0.483). Selectively missing ertapenem results in 2023–2024 restricted ertapenem-specific interpretation to 2025. In 2025, nine of 34 carbapenem-nonsusceptible isolates (26.5%) exhibited ertapenem-only nonsusceptibility. Among 252 cefotaxime-resistant urinary isolates without carbapenem nonsusceptibility, susceptibility was 29.8% to trimethoprim/sulfamethoxazole, 6.7% to ciprofloxacin, and 4.5% to levofloxacin. Nitrofurantoin susceptibility was 96.2% in Escherichia coli and 37.1% in Klebsiella pneumoniae . Among 463 cefotaxime-resistant isolates, 134 (28.9%) remained susceptible to ceftazidime; this proportion increased from 23.3% to 37.3% ( p = 0.006). Urinary carbapenem nonsusceptibility ranged from 3.7% in outpatients to 12.7% in inpatients. Conclusion Local antibiograms can guide the application of treatment guidance and prioritize genotyping and clinical studies of retained antibiotic activity. These laboratory findings do not establish resistance mechanisms, infection incidence, or treatment efficacy.

Authors

Institutions

Publication Details

Journal
Frontiers in Public Health
Published
2026-11-18
DOI
https://doi.org/10.3389/fpubh.2026.2011353
Primary Topic
Antibiotic Resistance in Bacteria
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Where guidance meets the local antibiogram: a three-year, single-center laboratory-based study of ertapenem-only nonsusceptibility, cefotaxime–ceftazidime discordance, and urinary susceptibility in Enterobacterales

Samadhi Patamatamkul, Thanyarat Phumthian, Sutasinee Puseekheaw
3 links
Frontiers in Public Health
Antibiotic Resistance in Bacteria
article

Where guidance meets the local antibiogram: a three-year, single-center laboratory-based study of ertapenem-only nonsusceptibility, cefotaxime–ceftazidime discordance, and urinary susceptibility in Enterobacterales

Samadhi Patamatamkul, Thanyarat Phumthian, Sutasinee Puseekheaw
article en

Abstract

Background Local antibiograms are essential for monitoring resistance and adapting treatment guidance to available antibiotics in resource-constrained settings. We examined resistance trends, discordant β-lactam susceptibility, and urinary susceptibility profiles in Enterobacterales to identify stewardship priorities. Methods This three-year, single-center, laboratory-based retrospective cross-sectional study included Enterobacterales from reporting years 2023–2025. We retained the first isolate per patient, species, and year. Resistance definitions incorporated the imipenem exception for Morganella , Proteus , and Providencia . Ertapenem-only nonsusceptibility required ertapenem nonsusceptibility and susceptibility to both meropenem and imipenem. Annual trends were assessed using the Cochran–Armitage test. Results Of 2,190 Enterobacterales isolates, 1,638 from 1,320 patients were retained. The proportion of isolates with carbapenem resistance declined from 8.4% in 2023 to 2.7% in 2025, and carbapenem nonsusceptibility from 12.6% to 5.4% (both p < 0.001). Cefotaxime resistance remained between 27.7% and 30.3% ( p = 0.483). Selectively missing ertapenem results in 2023–2024 restricted ertapenem-specific interpretation to 2025. In 2025, nine of 34 carbapenem-nonsusceptible isolates (26.5%) exhibited ertapenem-only nonsusceptibility. Among 252 cefotaxime-resistant urinary isolates without carbapenem nonsusceptibility, susceptibility was 29.8% to trimethoprim/sulfamethoxazole, 6.7% to ciprofloxacin, and 4.5% to levofloxacin. Nitrofurantoin susceptibility was 96.2% in Escherichia coli and 37.1% in Klebsiella pneumoniae . Among 463 cefotaxime-resistant isolates, 134 (28.9%) remained susceptible to ceftazidime; this proportion increased from 23.3% to 37.3% ( p = 0.006). Urinary carbapenem nonsusceptibility ranged from 3.7% in outpatients to 12.7% in inpatients. Conclusion Local antibiograms can guide the application of treatment guidance and prioritize genotyping and clinical studies of retained antibiotic activity. These laboratory findings do not establish resistance mechanisms, infection incidence, or treatment efficacy.

Frontiers in Public HealthVol. 14
Mahasarakham University (TH), Suddhavej Hospital (TH), Ubon Ratchathani University (TH)
Good health and well-being
Antibiotic Resistance in Bacteria
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon